Swiss vaccine developer Limma Tech get CARB-X grant
LimmaTech said, it will use the grant to advance preclinical development of its hexavalent vaccine candidate targeting Neisseria gonorrheae. Using...
Deregulation of new genomic techniques before decision
Although the required approval of 15 agriculture ministers was achieved in mid-December, the hotly debated proposal of the EU Commission to relax...
AstraZeneca to acquire Amolyt Pharma for up to US$1.05bn
Under the agreement set to close in Q3/2024, AstraZeneca will acquire Amolyt Pharma for US$800m upfront and potential milestone payments of US$250m....
Roche jumps ship on AC Immune
In recent trials, both Semorinemab, a monoclonal antibody (mAb) binding all forms of Tau, and Crenezumab, a mAb targeting multiple forms of misfolded...
2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...
Innate immunity merger raises €75m
Dutch Oxitope and Norwegian Arxx announced their merger to form Calluna Pharma Inc with the goal to develop therapies for inflammatory and fibrotic...
SeaBeLifeSeabelife SAS to develop next-gen dry AMD drug
French drug developer SeaBeLife SAS has bagged a €1.5m fund within the i-Nov 2024 innovation competition, which is part of the French government’s...